Insider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells $4,444,750.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Suma Krishnan also recently made the following trade(s):

• On Friday, December 13th, Suma Krishnan sold 25,000 shares of Krystal Biotech stock. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00.

Krystal Biotech Trading Up 1.1 %

Shares of KRYS stock opened at $179.38 on Friday. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34. The stock has a market cap of $5.17 billion, a P/E ratio of 59.99 and a beta of 0.87. The stock has a 50 day moving average of $163.50 and a 200 day moving average of $173.90.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm’s quarterly revenue was up 116.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.30 earnings per share. On average, research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on KRYS shares. Citigroup lifted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. HC Wainwright reiterated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective for the company. Chardan Capital upped their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $220.00.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors have recently modified their holdings of the business. Wilmington Savings Fund Society FSB acquired a new position in Krystal Biotech in the 3rd quarter worth about $40,000. GF Fund Management CO. LTD. acquired a new position in shares of Krystal Biotech during the 4th quarter worth approximately $95,000. Huntington National Bank lifted its position in shares of Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after buying an additional 283 shares in the last quarter. Covestor Ltd grew its stake in Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after acquiring an additional 642 shares during the period. Finally, KBC Group NV increased its holdings in Krystal Biotech by 25.9% in the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after acquiring an additional 132 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).